Choosing the best first biologic for Crohn’s in the ileum
Part of Digestive system clinical trials.
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (and if you can become pregnant, you must have a negative pregnancy test).
- You have a confirmed Crohn’s diagnosis.
- In the past 3 months, you had a colonoscopy showing significant ileal ulcers and inflammation (at least one ulcer larger than 5 mm).
- Your Crohn’s symptoms are at least moderate (HBI 5 or higher).
- You have never used Crohn’s biologic treatments before.
- You can and agree to follow the study plan and treatment schedule, with signed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at proteins from your body and gut bacteria to understand Crohn's disease better. You may join if you are about to have your first colonoscopy for suspected Crohn's and have not had any treatment yet.
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
This trial tests three different types of biologic medications to find which works best as a first treatment for moderate-to-severe ulcerative colitis.
This trial compares two different ways to choose your Crohn's treatment: one based on a special test of your cells (epigenetic markers) and the other based on standard care. It aims to see which approach works better for people with moderate to severe Crohn's disease.
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.